第一医药(600833) - 2015 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 16.67% to CNY 12,030,521.01 year-on-year[8] - Operating revenue grew by 8.32% to CNY 423,161,076.76 compared to the same period last year[8] - Operating profit increased to ¥15,056,121.86, representing a growth of 6.4% compared to ¥13,209,224.60 from the last period[22] - Net profit for the current period was ¥12,030,521.01, a rise of 16.6% from ¥10,311,330.23 in the previous period[22] - Total comprehensive income reached ¥62,259,578.47, compared to ¥9,811,685.61 in the previous period, indicating a substantial increase[22] - Basic and diluted earnings per share were both ¥0.0539, up from ¥0.0462 in the last period[22] Cash Flow - Net cash flow from operating activities increased by 61.92% to CNY 50,605,286.81 compared to the previous year[8] - The total cash inflow from operating activities for Q1 2015 was CNY 508,562,157.32, an increase of 11.5% compared to CNY 455,985,701.16 in the same period last year[25] - The net cash flow from operating activities was CNY 50,605,286.81, up 62% from CNY 31,252,383.15 in Q1 2014[25] - The cash inflow from investment activities for the parent company was CNY 8,256,139.55, compared to CNY 11,000.00 in Q1 2014[26] Assets and Liabilities - Total assets increased by 6.96% to CNY 1,156,217,745.94 compared to the end of the previous year[8] - Total liabilities reached CNY 442,987,447.55, compared to CNY 430,009,165.62 at the beginning of the year[15] - Shareholders' equity rose to CNY 713,230,298.39 from CNY 650,970,719.92[15] - Current assets totaled CNY 596,342,164.45, slightly up from CNY 585,995,376.38 at the start of the year[14] - Non-current assets increased to CNY 559,875,581.49 from CNY 494,984,509.16[14] Shareholder Information - The number of shareholders reached 19,117 at the end of the reporting period[10] - The largest shareholder, Shanghai Xinduda Commercial (Group) Co., Ltd., holds 23.39% of shares[10] Inventory and Receivables - Accounts receivable grew to CNY 151,853,938.25 from CNY 131,415,698.66[14] - Inventory decreased to CNY 219,816,417.52 from CNY 273,525,913.70[14] Strategic Focus - The company is focusing on expanding its market presence and enhancing product development strategies[20]